

**Amendments to the Specification:**

Please amend the specification as shown:

Please delete the paragraph on page 8, line 23 to page 9, line 2 and replace it with the following paragraph:

In another embodiment the galanin analog is selected from the group consisting of :

- (i) Galanin-(2-29) (i. e. deletion of first amino acid);
- (ii) Galanin-(3-29) (i. e. deletion of first 2 amino acids);
- (iii) Galanin- (1-15) (i. e. deletion of amino acids 16-29/30);
- (iv) Galanin- (1-16) (ie. deletion of amino acids 17-29/30);
- (v) M40:galanin- (1-13)-Pro-Pro-Ala-Leu-Ala-Leu-Ala-amide (**SEQ ID NO: 30**);
- (vi) M15 (galantide): Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH<sub>2</sub> (SEQ ID NO: **43 31**);
- (vii) M35 : galanin(1-13)-bradykinin (2-9) amide;
- (viii) M32: galanin(1-13)-neuropeptide Y (25-36) amide; and
- (ix) C7: galanin(1-13)-spantide amide.

Please delete the paragraph on page 21, line 25 to page 22, line 5 and replace it with the following paragraph:

In another embodiment the galanin analog is selected from the group consisting of :

- (i) Galanin-(2-29) (i. e. deletion of first amino acid);
- (ii) Galanin-(3-29) (i. e. deletion of first 2 amino acids);
- (iii) Galanin- (1-15) (i. e. deletion of amino acids 16-29/30);
- (iv) Galanin- (1-16) (ie. deletion of amino acids 17-29/30);
- (v) M40:galanin- (1-13)-Pro-Pro-Ala-Leu-Ala-Leu-Ala-amide (**SEQ ID NO: 30**);
- (vi) M15 (galantide): Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH<sub>2</sub> (SEQ ID NO: **43 31**);
- (vii) M35 : galanin(1-13)-bradykinin (2-9) amide;
- (viii) M32: galanin(1-13)-neuropeptide Y (25-36) amide; and
- (ix) C7: galanin(1-13)-spantide amide.